Development of cancer therapeutic technology by functional measurement and control of cell division.

我们已经开发了一种技术，用于癌症的早期诊断和治疗监测，这是我们发现的一种癌症标志物。我们还开发了用于发现抗癌药物的Bradeion试验技术。因此，我们成功地开发了癌症诊断系统和试剂盒。此外，我们成功地进行了Bradeion的结构分析和表征，并通过建立测定其酶活性的方法，开发了测定其抑制作用的技术。在研究期间的最后一年，我们使用荧光相关光谱（FCS）检测患者血清中的单个靶分子。该全自动共聚焦激光显微镜可在一分钟内测量10 pI的血清，每个样品的成本仅为1美元。一周内可测量3000个样品。在室温下保存一周的样品中，数据可重复。样品在冰箱里可以保存一个月。直到现在，虽然有许多蛋白质结构分析的项目涌入，但具有独创性的材料的结构呈现终究没有成功。另一方面，我们成功地分析了癌症标志物Bradeion的结构，结果我们将范围缩小到只有一种有用的材料，并将符合目的的方法集中在一起。选择抗癌药物的候选药物不仅要考虑其疗效，而且要考虑其低毒性。因此，我们使用果蝇和嵌合体小鼠（专利）为毒性检查配备了动物模型。我们从Bradeion蛋白的结构分析中研究了一种抑制剂，并使用FCS进行了高通量筛选。我们的目标是开发一种抗癌剂，通过对筛选的候选药物进行评估，并通过动物模型进行毒性检查。

We have developed a technology for early diagnosis and cure monitor of cancer with Bradeion, a cancer marker we found. We have also developed the technology of Bradeion assay for discovering anticancer agent. As a result, we succeeded in the development of a cancer diagnosis system and kit. In addition, we succeeded in the structure analysis and the characterization of Bradeion, and development of the technology measuring inhibiting effect by the establishment of the method measuring its enzyme activity. In the last year of the study period, we used a fluorescence correlation spectroscopy (FCS) detecting single target molecule in patient serum. This full automatic machine with confocal laser microscope can measure using 10 pI of serum with a minute, and it costs only \1 per specimen. 3, 000 samples can be measured within one week. The data is reproducible in the samples stored at room temperature for a week. The samples preserved in a refrigerator are stable for a month.The structure presentation of a material with originality did not succeed after all until now, though many projects for protein structure analysis flooded. On the other hand, we succeed in the structure analysis of the cancer marker, Bradeion, as a result that we narrowed down to only one useful material and centralized the methodology that complies with a purpose. It is not only medicinal benefits but also less toxicity that is important to select the candidate of and cancer drug. We therefore equipped animal models for the toxic examination using a Drosophila and a chimera mouse(patented). We investigate an inhibitor from structure analysis of Bradeion protein and perform a high throughput screening using the FCS. We aim at development of an anticancer agent, by performing the evaluation of the candidate selected by the screening and a toxic examination by the animal model.